Praxis Precision Medicines Inc. (PRAX) PT Raised to $155 at Guggenheim

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. VRTX
4. WMT
5. LMT
6. RXST
7. SPY
8. SPGI
9. RIVN
10. CMPS

Go back to Praxis Precision Medicines Inc. (PRAX) PT Raised to $155 at Guggenheim

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 4, 2025 8:30 AM EDT

RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in last 28 days

Initiated two registrational studies for Developmental and Epileptic Encephalopathies (DEEs) programs: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A Gain-of-Function (GoF) with elsunersen

Relutrigine granted U.S. FDA Breakthrough Therapy Designation for the treatment of seizures associated with SCN2A and SCN8A DEEs, enabling expedited development

Cash and investments of approximately $447... More

Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine

August 4, 2025 8:00 AM EDT

Dosing with vormatrigine over 8 weeks led to 56.3% median reduction in seizure frequency

Approximately 22% of patients reached 100% reduction in seizure frequency in the last 28 days on treatment

Rapid and sustained response, with over 54% of patients achieving 50% response in the first week

Vormatrigine was generally well tolerated and continues to demonstrate favorable safety profile

BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) --... More